

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Agrawal et al.
Application No.: 10/757,345 Group: 1633
Filed: January 14, 2004 Examiner: Hill, Kevin Kai
Confirmation No.: 3490

For: MODULATION OF IMMUNOSTIMULATORY PROPERTIES
OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING
MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service
with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: _____ Signature: _____

Printed Name: _____

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☐ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the
national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional
application, including a CPA, or a Request for Continued Examination).
- ☒ under 37 CFR 1.97(c) together with either
☐ a Statement under 37 CFR 1.97(e), as check below, or
☒ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
☐ a Statement under 37 CFR 1.97(c), as check below, or
☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Statement Under 37 CFR 1.97(c)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
 - ☒ Copies of the cited references are submitted herewith.
 - ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contained copies of the cited referenced]
 - ☒ The listed references were cited in the enclosed European Search Report in a counterpart foreign application.
 - ☐ The “concise explanation” requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

☐ Applicant request that the following non-published pending application be considered:

Examiner's Initials

_____ U.S. Patent Application No. [], by [inventor(s), filed [], Docket No.: []

_____ U.S. Patent Application No. [], by [inventor(s), filed [], Docket No.: []

_____ U.S. Patent Application No. [], by [inventor(s), filed [], Docket No.: []

Examiner

Date

☐ The specifications for the above-cited applications are identical to the Instant Specification. Therefore, only a copy of the current claims for each above-cited application is enclosed.

☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending application indicating which references were considered with the net office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of Payment:

☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

☒ Please charge Deposit Account 50-2285 in the amount of \$180.00.

☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 50-2285.

Respectfully submitted,

Date: November 5, 2007

By: /s/ Joseph C. Zucchero
Joseph C. Zucchero
Registration No. 55,762

Keown & Zucchero, LLP
500 West Cummings Park
Suite 1200
Woburn, MA 01801
Telephone: 781-938-1805
Facsimile: 781-938-4777